The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Torshin I.Iu.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna

Gromova O.A.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna;
kafedra farmakologii i klinicheskoĭ farmakologii Ivanovskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Sardaryan I.S.

Moscow Institute of Physics and Technology

Fedotova L.E.

Ivanovo State Medical Academy, Ivanovo

A comparative chemoreactome analysis of mexidol

Authors:

Torshin I.Iu., Gromova O.A., Sardaryan I.S., Fedotova L.E.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(1‑2): 75‑83

DOI: 10.17116/jnevro20171171275-84

Read: 6414 times

Download PDF (RU)
Contact the author
Table of contents

A COMPARATIVE CHEMOREACTOME ANALYSIS OF MEXIDOL
A COMPARATIVE CHEMOREACTOME ANALYSIS OF MEXIDOL

To cite this article:

Torshin IIu, Gromova OA, Sardaryan IS, Fedotova LE. A comparative chemoreactome analysis of mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(1‑2):75‑83. (In Russ.)
https://doi.org/10.17116/jnevro20171171275-84

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
Resu­lts of the inte­rnational multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the effi­cacy and safety of the sequential therapy with ethy­lmethylhydroxypyridine succinate in patients in the acute and early reco­very periods of ischemic stroke (MIR). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):40-53
Personal characteristics of patients with cere­bral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):51-56
Modern approaches to diagnosis and treatment of postinfectious asthenic syndrome in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):42-52
The known and new ideas about the mechanism of action and the spectrum of effe­cts of Mexi­dol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50
The impact of Mexi­dol on improving quality of life para­meters and functional kidney status as part of complex therapy for cognitive impairments in como­rbid patients with microalbuminuria against the background of arte­rial hype­rtension and type 2 diabetes mellitus. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(4):478-478
Targets of rational neuroprotection in the therapy of chro­nic cere­bral ischemia and the possibilities of achieving them. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):96-101
The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(4):49-59
Study of drug-drug inte­ractions between Mexi­dol and thro­mbolytic drugs. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):139-144
Abstract:

Objective. To compare mexidol with control molecules (choline alfoscerate, piracetam, glycine, semax) using chemoreactome analysis. Material and methods. The chemical structure of mexidol was compared to molecule metabolites extracted from the Human Metabolome Database (HMDB) and a drug database. More than 40 000 of metabolites from HMDB were used as a model of human metabolome. Results and conclusion. The chemoreactome analysis showed that mexidol may be (1) an agonist of acetylcholine and GABA-A receptors; (2) an anti-inflammatory agent, the effects of which are carried out by inhibiting the synthesis of pro-inflammatory prostaglandins; (3) a neurotrophic agent with neuroprotective properties; (4) a coagulation inhibitor; (5) a diabetes medication and (6) a hypolipidemic agent. Compared to «control» molecules, mexidol has a more pronounced safety profile (a lower impact on serotonin, dopamine and adrenergic receptors, a lesser degree of interaction with the potassium channels of the heart, MAO and P450 cytochromes). The results of modeling allow to specify the mechanisms of action of mexidol at the molecular level.

Keywords:

mexidol
neuroprotection
chemoreactome analysis
chemoinformatics
forecasting

Authors:

Torshin I.Iu.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna

Gromova O.A.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna;
kafedra farmakologii i klinicheskoĭ farmakologii Ivanovskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Sardaryan I.S.

Moscow Institute of Physics and Technology

Fedotova L.E.

Ivanovo State Medical Academy, Ivanovo

Close metadata

References:

  1. Voronina T.A. Meksidol: spektr farmakologicheskikh effektov. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(12):86-90.
  2. Shchul'kin A.V. Vliyanie meksidola na razvitie fenomena eksaitotoksichnosti neironov in vitro. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(2):35-39.
  3. Shchul'kin A.V., Yakusheva E.N., Chernykh I.V. Raspredelenie meksidola v strukturakh golovnogo mozga, ego kletochnykh elementakh i subkletochnykh fraktsiyakh. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;114(8):69-72.
  4. Torshin I.Yu., Gromova O.A. Ekspertnyi analiz dannykh v molekulyarnoi farmakologii. M.: Izd. MTsNMO; 2012.
  5. Torshin IY. Bioinformatics in the post-genomic era: physiology and medicine. Nova Biomedical Books. NY, USA. 2007.
  6. Zhuravlev Yu.I., Rudakov K.V., Torshin I.Yu. Algebraicheskie kriterii lokal'noi razreshimosti i regulyarnosti kak instrument issledovaniya morfologii aminokislotnykh posledovatel'nostei. Trudy MFTI. 2011;3:4:67-76.
  7. Rudakov K.V., Torshin I.Yu. Ob otbore informativnykh znachenii priznakov na baze kriteriev razreshimosti v zadache raspoznavaniya vtorichnoi struktury belka. DAN. 2011;441:1:1-5.
  8. Torshin IY, Rudakov KV. On the application of the combinatorial theory of solvability to the analysis of chemographs: Part 2. local completeness of invariants of chemographs in view of the combinatorial theory of solvability. Pattern Recognition and Image Analysis. 2014;24:2:196-208.
  9. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K, Arndt D, Sawhney S, Fung C, Nikolai L, Lewis M, Coutouly MA, Forsythe I, Tang P, Shrivastava S, Jeroncic K, Stothard P, Amegbey G, Block D, Hau DD, Wagner J, Miniaci J, Clements M, Gebremedhin M, Guo N, Zhang Y, Duggan GE, Macinnis GD, Weljie AM, Dowlatabadi R, Bamforth F, Clive D, Greiner R, Li L, Marrie T, Sykes BD, Vogel HJ, Querengesser L. HMDB: the Human Metabolome Database. Nucleic Acids Res. 2007;35:521-526.
  10. Olianas MC, Dedoni S, Onali P. Protection from interferon-beta-induced neuronal apoptosis through stimulation of muscarinic acetylcholine receptors coupled to ERK1/2 activation. Br J Pharmacol. 2016;173(19):2910-2928.
  11. Lin NH, Gunn DE, Ryther KB, Garvey DS, Donnelly-Roberts DL, Decker MW, Brioni JD, Buckley MJ, Rodrigues AD, Marsh KG, Anderson DJ, Buccafusco JJ, Prendergast MA, Sullivan JP, Williams M, Arneric SP, Holladay MW. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. J Med Chem. 1997;40(3):385-390.
  12. Nakamura M, Jang IS. Muscarinic M4 receptors regulate GABAergic transmission in rat tuberomammillary nucleus neurons. Neuropharmacology. 2012;63(6):936-44.
  13. Vandevrede L, Tavassoli E, Luo J, Qin Z, Yue L, Pepperberg DR, Thatcher GR. Novel analogues of chlormethiazole are neuroprotective in four cellular models of neurodegeneration by a mechanism with variable dependence on GABA(A) receptor potentiation. Br J Pharmacol. 2014;171(2):389-402.
  14. Avolio E, Mahata SK, Mantuano E, Mele M, Alo R, Facciolo RM, Talani G, Canonaco M. Antihypertensive and neuroprotective effects of catestatin in spontaneously hypertensive rats: interaction with GABAergic transmission in amygdala and brainstem. Neuroscience. 2014;270:48-57.
  15. Young W. Spinal cord regeneration. Cell Transplant. 2014;23(4-5):573-611.
  16. Gaikwad AB, Viswanad B, Ramarao P. PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. Pharmacol Res. 2007;55(5):400-407.
  17. Braga RC, Alves VM, Silva MF, Muratov E, Fourches D, Tropsha A, Andrade CH. Tuning HERG out: antitarget QSAR models for drug development. Curr Top Med Chem. 2014;14(11):1399-1415.
  18. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440(7083):463-469.
  19. Palee S, Apaijai N, Shinlapawittayatorn K, Chattipakorn SC, Chattipakorn N. Acetylcholine Attenuates Hydrogen Peroxide-Induced Intracellular Calcium Dyshomeostasis Through Both Muscarinic and Nicotinic Receptors in Cardiomyocytes. Cell Physiol Biochem. 2016;39(1):341-349.
  20. Dorszewska J, Florczak J, Rozycka A, Jaroszewska-Kolecka J, Trzeciak WH, Kozubski W. Polymorphisms of the CHRNA4 gene encoding the alpha4 subunit of nicotinic acetylcholine receptor as related to the oxidative DNA damage and the level of apoptotic proteins in lymphocytes of the patients with Alzheimer's disease. DNA Cell Biol. 2005;24(12):786-794.
  21. Li Y, King MA, Meyer EM. alpha7 nicotinic receptor-mediated protection against ethanol-induced oxidative stress and cytotoxicity in PC12 cells. Brain Res. 2000;861(1):165-167.
  22. Stegemann A, Bohm M. The alpha7 nicotinic acetylcholine receptor agonist tropisetron counteracts UVA-mediated oxidative stress in human dermal fibroblasts. Exp Dermatol. 2016; Exp Dermat: 101111/exd13220.
  23. Shan KR, Qi XL, Long YG, Nordberg A, Guan ZZ. Decreased nicotinic receptors in PC12 cells and rat brains influenced by fluoride toxicity — a mechanism relating to a damage at the level in post-transcription of the receptor genes. Toxicology. 2004;200(2-3):169-177.
  24. Han Z, Shen F, He Y, Degos V, Camus M, Maze M, Young WL, Su H. Activation of alpha-7 nicotinic acetylcholine receptor reduces ischemic stroke injury through reduction of pro-inflammatory macrophages and oxidative stress. PLoS One. 2014;9(8):105711.
  25. Navarro E, Buendia I, Parada E, Leon R, Jansen-Duerr P, Pircher H, Egea J, Lopez MG. Alpha7 nicotinic receptor activation protects against oxidative stress via heme-oxygenase I induction. Biochem Pharmacol. 2015;97(4):473-481.
  26. Gao Z, Zhang H, Liu J, Lau CW, Liu P, Chen ZY, Lee HK, Tipoe GL, Ho HM, Yao X, Huang Y. Cyclooxygenase-2-dependent oxidative stress mediates palmitate-induced impairment of endothelium-dependent relaxations in mouse arteries. Biochem Pharmacol. 2014;91(4):474-482.
  27. Nishizaki T, Matsuoka T, Nomura T, Sumikawa K. Modulation of ACh receptor currents by arachidonic acid. Brain Res Mol Brain Res. 1998;57(1):173-179.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.